- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2014
- Public Summary Document (PSD) November 2014 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2014 PBAC Meeting - Word
Pertuzumab; trastuzumab; trastuzumab emtansine – November 2014
Pertuzumab; 420 mg/14 mL injection, 1 x 14 mL vial; Perjeta®; Trastuzumab; 150 mg injection, 1 × 150 mg vial, 60 mg injection, 1 × 60 mg vial; Kadcyla®
Last updated
8 March 2018